Clinical Trials on Wet Age-related Macular Degeneration (wAMD)

Total 1381 results

AbbVie
AbbVie

Enrolling by invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Gene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMD

United States
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
Oraya Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)

Macular Degeneration | Age-related Macular Degeneration | AMD | Wet AMD | Wet Age-related Macular Degeneration

United Kingdom, Italy
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）

Wet Age-related Macular Degeneration (wAMD)

China
Novartis Pharmaceuticals

Withdrawn

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (CANARI)

Wet Age-related Macular Degeneration (Wet AMD)
Hoffmann-La Roche

Recruiting

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration | nAMD

China
Oraya Therapeutics, Inc.

Completed

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | AMD | Wet AMD | Wet Age-Related Macular Degeneration

United Kingdom, Czech Republic, Austria, Germany, Italy
Exegenesis Bio

Recruiting

A Study of EXG102-031 in Patients With wAMD (Everest)

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

United States, Japan, Australia, Korea, Republic of
Hoffmann-La Roche

Recruiting

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Neovascular Age-related Macular Degeneration (nAMD)

Belgium, Korea, Republic of, Germany, Spain, United Kingdom, Australia, Italy, Argentina, Israel, Austria, Brazil, France, Singapore, Switzerland, Taiwan, Turkey
Novartis Pharmaceuticals

Active, not recruiting

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal (BLUESKY-PT)

Neovascular Age-related Macular Degeneration (nAMD)

Portugal
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Neovascular Age-related Macular Degeneration (nAMD)

United States
Ocugenix Corporation

Not yet recruiting

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)

United States
Aerie Pharmaceuticals
Alcon Research

Recruiting

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

Neovascular Age-related Macular Degeneration (nAMD)

United States
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Neovascular Age-related Macular Degeneration (nAMD)

United States
HuidaGene Therapeutics Co., Ltd.
Eye & ENT Hospital of Fudan University; Tianjin Medical University Eye Hospital

Recruiting

CRISPR/cas13-medIated RNA tarGeting tHerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Neovascular Age-related Macular Degeneration(nAMD)

China
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) (PEREGRINE)

Age-related Macular Degeneration (AMD)
King's College Hospital NHS Trust
King's College London

Active, not recruiting

Stereotactic Radiotherapy for Wet AMD (STAR) (STAR)

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United Kingdom
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Regeneron Pharmaceuticals

Completed

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Neovascular Wet Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Exudative Macular Degeneration | Neovascular Age-elated Macular Degeneration (Wet AMD)

United States
Regeneron Pharmaceuticals

Not yet recruiting

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (SPECTRUM-US)

Visual Impairment | Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD) | Wet Age-related Macular Degeneration (AMD)
Oregon Health and Science University

Recruiting

OCT Angiography in Wet AMD

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United States
Regeneron Pharmaceuticals

Active, not recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration (nAMD)

India
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
AbbVie

Completed

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
AbbVie
AbbVie

Recruiting

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Caregen Co. Ltd.
CBCC Global Research

Not yet recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Age-related Wet Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Hoffmann-La Roche

Withdrawn

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (Diagrid)

Neovascular Age-Related Macular Degeneration

Denmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
Novartis Pharmaceuticals

Terminated

Russian Registry of Patients With nAMD

Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals

Completed

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Neovascular Age Related Macular Degeneration

United States
REGENXBIO Inc.

Completed

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
RemeGen Co., Ltd.

Recruiting

Efficacy and Safety of RC28-E Versus Aflibercept

Wet Age-related Macular Degeneration

China
Sinocelltech Ltd.

Recruiting

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Wet Age-related Macular Degeneration

China
EyePoint Pharmaceuticals, Inc.

Active, not recruiting

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (DAVIO2)

Wet Age-related Macular Degeneration

United States
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
EyePoint Pharmaceuticals, Inc.

Completed

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Wet Age-related Macular Degeneration

United States
Bayer

Completed

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration

India
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Alkahest, Inc.

Completed

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Qilu Pharmaceutical Co., Ltd.

Completed

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Wet Age-related Macular Degeneration

China
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Completed

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Maculopathy, Age-Related

United States
Ocular Therapeutix, Inc.
Duke University; Fortrea

Recruiting

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Neovascular Age-Related Macular Degeneration

China

Clinical Trials on Wet Age-related Macular Degeneration (wAMD)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations